

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7214273

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALEX AIMETTI	12/08/2020
JOSEPH HULIHAN	12/08/2020
SCOTT BRAUNSTEIN	12/08/2020
RECEIVING PARTY DATA	
Name:	MARINUS PHARMACEUTICALS, INC.
Street Address:	5 RADNOR CORPORATE CENTER
Internal Address:	100 MATSONFORD ROAD, SUITE 500
City:	RADNOR
State/Country:	PENNSYLVANIA
Postal Code:	19087
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17683624
CORRESPONDENCE DATA	
Fax Number:	(617)317-1037
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-702-7741
Email:	Doreen.fisher@hoganlovells.com
Correspondent Name:	RHIANNA LINDOP
Address Line 1:	HOGAN LOVELLS US LLP
Address Line 2:	125 HIGH STREET, SUITE 2010
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	761996.120010
NAME OF SUBMITTER:	RHIANNA LINDOP
SIGNATURE:	/RHIANNA LINDOP/
DATE SIGNED:	03/09/2022
Total Attachments: 4	
source=Assignment_761996_120010#page1.tif	
source=Assignment_761996_120010#page2.tif	

source=Assignment_761996_120010#page3.tif

source=Assignment_761996_120010#page4.tif

ASSIGNMENT

WHEREAS, we, **Alex Aimetti, Joseph Hulihan, and Scott Braunstein**, (hereinafter referred to as “Assignors”) have made certain new and useful inventions described and/or claimed in the patent application entitled:

GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX

as set forth in this International Patent Application No.: **PCT/US2020/063648**; filed on **December 7, 2020**; and

AND WHEREAS, **Marinus Pharmaceuticals, Inc.**, a corporation organized and existing under the laws of Delaware, and having a usual place of business at **5 Radnor Corporate Center, 100 Matsonford Road, Suite 500, Radnor, PA 19087** (hereinafter referred to as “Assignee”), is desirous of acquiring the entire right, title and interest in and to said inventions and in and to any and all Letters Patent of the United States and foreign countries which may be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged we do hereby sell, assign, transfer and set over unto Assignee, its lawful successors and assigns, our entire right, title and interest in and to said inventions, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) any PCT International Application and all national stage applications based thereon, all divisions, continuations, continuations-in-part, reissues, reexaminations and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement, treaties and laws; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and

assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

.

IN TESTIMONY WHEREOF, we have hereunto set our hands.

ASSIGNOR (Inventor 1)

Alex Aimetti

Signature

Alex Aimetti

Print Name

December 8, 2020 | 12:01 PM PST

Execution Date

IN TESTIMONY WHEREOF, we have hereunto set our hands.

ASSIGNOR (Inventor 2)

Joseph Hulihan

Signature

Joseph Hulihan

Print Name

December 8, 2020 | 12:32 PM PST

Execution Date

Acknowledged and Accepted by:

Marinus Pharmaceuticals, Inc.

Martha Manning


Print Name: Martha E. Manning, Esq.

Print Title: VP, General Counsel & Corporate Secretary

Date: December 8, 2020 | 3:35 PM EST

IN TESTIMONY WHEREOF, we have hereunto set our hands.

ASSIGNOR (Inventor 3)



Signature

Scott BRAUNSTEIN

Print Name

December 8, 2020 | 3:22 PM EST

Execution Date

Acknowledged and Accepted by:

Marinus Pharmaceuticals, Inc.



Print Name: Martha E. Manning, Esq.

Print Title: VP, General Counsel & Corporate Secretary

Date: December 8, 2020 | 3:35 PM EST